Improving the success rate of kidney transplants Innovative therapies are among the first in the world.

For patients with end-stage kidney disease, receiving a kidney transplant is one of the best ways to save their lives.
however, patients with highly allergenic kidney transplants carry antibodies that can cross-react with donor organs, which trigger immune rejection of transplanted organs, preventing them from surviving long-term in patients.
Imlifidase is an antibody lysase that specificly targets IgG and inhibits IgG-mediated immune responses.
it to work quickly and can crack IgG antibodies and inhibit their activity within hours of being given.
use imlifidase before surgery to quickly remove IgG antibodies from the patient's body, increasing the chances of survival of the transplanted organ.
Imlifidase has been awarded a PRIME drug by the European Union's EMA.
photo source: Hansa's official website In March, Hansa published long-term follow-up results that showed that 89 percent of the 46 patients who received an organ transplant after receiving imlifidase were still alive two years after receiving the transplant.
it is worth noting that imlifidase also has the potential to improve gene therapy, and in July this year Hansa reached an agreement with Sarepta Therapeutics to develop and promote imlifidase as a pretreatment to expand the use of gene therapy for the treatment of Duchy muscular dystrophy (DMD) and leg-band muscular dystrophy (LGMD).
because many DMD and LGMD patients have been infected with AAV, they have high levels of mesoth antibodies against AAV.
these antibodies can prevent gene therapy from being effective, preventing these patients from accepting this innovative treatment option.
Imlifidase can remove IgG antibodies against AAVs, making gene therapy possible for drugging and re-dosing.
resources: the EU Commission grants approval for IdefirixTM (imlifidase) in highlyly sensitized kidney patients in the European Union. Retrieved August 26, 2020, from.